Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
Case seriesHumans
- Design
- Case series
- Subjects
- Two children with autism (a 13-year-old boy and a 15-year-old boy)
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Expressive language (mean length of utterance), autism severity (Childhood Autism Rating Scale, Second Edition), atopic symptoms and safety.
What the authors reported
The first boy (aged 13) showed significant improvement in expressive language (mean length of utterance) and in overall autism severity (CARS-2), and his atopic symptoms diminished. No side effects were reported. The second boy (aged 15) showed noticeable and rapid improvements in cognition, behaviours and sociability; the abstract gives no scores for him.
Limits of this study
Two case reports with no control group; findings cannot be generalised. The authors call for double-blind trials to test PEA in autism. Funding and conflicts not stated in the abstract.
Source
PubMed 26491593 · doi:10.1155/2015/325061
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.